We have repeatedly observed that some BRAF‐mutated sensitive melanoma cell lines treated with low‐dose suboptimal vemurafenib (i.e., 20 nmol/L and up to 100 nmol/L depending on the cell lines) may paradoxically proliferate. This evidence concerns the gene BRAF and melanoma.